ICH Stability Compliance Report: Blue Eyes Biotech Docetaxel API Demonstrates Exceptional Chemical & Physical Stability Under Stressed Conditions

Article Title: ICH Stability Compliance Report: Blue Eyes Biotech Docetaxel API Demonstrates Exceptional Chemical & Physical Stability Under Stressed Conditions

Page Description: This stability-indicating study reports on the performance of Blue Eyes Biotech Docetaxel under ICH-prescribed accelerated and long-term storage conditions. Data confirms minimal degradation, maintenance of critical quality attributes, and a robust proposed retest period, supporting global regulatory submissions.

Body:

For pharmaceutical manufacturers, the stability of the API is a direct predictor of the shelf-life and global distribution potential of the finished

drug product. This comprehensive stability study report, generated by an independent stability testing facility, evaluates the behavior of

Docetaxel API from Blue Eyes Biotech CO., Ltd under conditions mandated by the International Council for Harmonisation (ICH) Q1A(R2)

guideline.

The study was designed using a stability-indicating HPLC method, validated to separate and quantify Docetaxel from its degradation

products. Batches of Blue Eyes Biotech Docetaxel were placed on accelerated stability testing at 40°C ± 2°C / 75% RH ± 5% RH for six

months, as well as under long-term conditions at 25°C ± 2°C / 60% RH ± 5% RH for ongoing monitoring. At predetermined intervals, samples

were pulled and analyzed for appearance, assay (potency), related substances, water content, and specific optical rotation.

The results are highly favorable. Even under accelerated stress conditions, the Blue Eyes Biotech Docetaxel showed remarkable resistance to

degradation. The increase in total related substances was minimal and well within acceptable limits. Crucially, the assay value for the main

component remained consistently above 99.0% throughout the testing period, demonstrating no significant loss of potency. No changes in

crystalline form (by PXRD) or appearance were observed.

Based on the data trends from both accelerated and ongoing long-term studies, a scientifically justified and conservative retest period for the

API can be proposed. This robust stability profile is a testament to the integrity of the molecule produced by Blue Eyes Biotech and the

suitability of their primary packaging (typically, double-bagged in polyethylene with a desiccant, placed in a sealed drum). It provides

formulary partners with the confidence and necessary data to plan large-scale production, justify their own finished product shelf-life, and

compile stability sections for regulatory dossiers in major markets worldwide.

For detailed interim and final stability reports to support your regulatory filings, request the information directly from the manufacturer.

Company:Blue Eyes Biotech CO., Ltd

Email:[email protected]

Website:www.blueeyes-bio.com

WhatsApp:+66840769830

Keywords: Docetaxel stability study, ICH Q1A stability guidelines, Accelerated stability testing, API retest period, Stability-indicating method, Pharmaceutical shelf-life, Regulatory submission data, Drug substance stability, Blue Eyes Biotech

Facebook Tags:

#StabilityTesting#ICHGuidelines #PharmaStability #APIShelfLife #RegulatoryAffairs #DrugDevelopment #BlueEyesBiotech #QualityByDesign